Celgene Corp.

86 Morris Avenue,
Summit, New Jersey 07901
United States,
(908) 673-9000

Celgene Corp. is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. Celgene Corp. was established in 1980 and is headquartered in Summit, New Jersey.

M&A Summary

Buy vs Sell

Year ≤ '13 '14 '15 '16 '17 '18 T
Buy (1.2/yr) # 8 - 2 1 2 1 14
vol $7.4B $7.2B $600M $345M $1.1B $16.7B
Sell (0.0/yr) # 1 - - - - - 1
vol $103M $103M

Top M&A Advisors

Financial Deals
Sign-up to View
Sign-up to View
Sign-up to View
Legal Deals
Sign-up to View
Sign-up to View

Deal Values

> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
TOTAL Sign-up to View
Largest Receptos, Inc.
$7.2B (2015-07-14)
Sell # Total
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
Total Sign-up to View
Largest Penn Pharmaceutical Services Ltd.
$103M (2007-04-26)

According to our data here at Mergr, Celgene has acquired 14 companies, including 7 in the last 5 years. It has also divested 1 asset.

Celgene’s largest acquisition to date was in 2015, when it acquired Receptos for $7.2B. It’s largest disclosed sale occurred in 2007, when it sold Penn Pharmaceutical Services to Lloyds TSB Development Capital for $103M. Celgene has acquired in 4 different US states, and 3 countries. The Company’s most targeted sectors include life science (79%) and medical products (22%).

When analyzing the life science sector as a whole, according to Mergr, in the last 3 years, there are 410 life science companies that have made at least 1 acquisition, 15 have acquired at least 5 companies, and 2 have acquired more than 10 companies. The most prolific strategic life science acquirer over the past 3 years is Eurofins Scientific SA, with 29 acquisitions. The most prolific private equity acquirer in the life science sector over the past 3 years is Ampersand Capital Partners with 5 platform acquisitions.

Join Mergr and gain access to Celgene’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.

What's Mergr?

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
  • 3.4K Private Equity Firms
  • 119K M&A Transactions
  • 129K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 2.8K M&A Advisors
    (Investment Banks and Law Firms)
  • 35K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.